J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
After Genmab’s exit two more ADCs enter human trials.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
